Document text
Principal Investigator: George N. Pavlakis
Organization: DIVISION OF BASIC SCIENCES - NCI
Fiscal Year: 2021
Award: $1,489,039
Funding agency: National Cancer Institute
We explored the biology of IL-15 and showed that efficient production of IL-15 is possible only by co-expression in the same cell with the so-called IL-15 Receptor-alpha. We also showed that a second form of IL-15 (SSP IL-15) previously identified in humans and rodents as intracellular or nuclear IL-15 is also efficiently secreted from the cells when co-expressed with the IL-15 Receptor alpha. These results shed new light in the biology and regulation of IL-15 and provide methods for the efficient production and clinical application of this cytokine. Cell lines overproducing soluble bioactive IL-15/IL-15 Receptor alpha heterodimers have been constructed and were used for the production of the bioactive form of IL-15 found in the body and for the development of cGMP material for clinical trials. IL-15 is of interest due to its ability to stimulate the growth, activation and survival of lymphocytes, including CD8 and NK cells. Thus, IL-15 has been considered for cancer immunotherapy and for support of the growth of cytotoxic cell clones after adoptive transfer. Other proposed uses of IL-15 are in lymphopenia, in supporting NK cell growth and activation after NK transfer, and as vaccine adjuvant. We have shown that IL-15 injection accelerates the recovery of lymphocytes in mice rendered lymphopenic after treatment with cytotoxic drugs. We also showed that hetIL-15 can replace the need for lymphodepletion in Adoptive Cell Transfer (ACT), since the transferred cells can survive, proliferate and enter the tumors after hetIL-15 treatment. This may have important clinical implications for ACT protocols. We have used the previously developed technologies of RNA optimization to optimize expression of IL-15 cytokine, and have shown that we can over-produce bioactive cytokine after DNA delivery in mice and macaques. DNA delivery of vectors expressing heterodimeric IL-15 leads to systemically active levels of cytokine and the increased proliferation of NK and T cells. We have shown that hetIL-15 greatly increases lymphocyte infiltration in several tumors in mouse models and in macaques, suggesting a general method to increase lymphocyte infiltration, which is associated with anti-tumor activity. On the basis of these results, we have initiated first-in-human clinical trials of hetIL-15 in metastatic cancers and also in combination with anti-PD-1 check point inhibitor (NCT02452268; collaboration with Novartis). In addition to cancer immunotherapy, IL-15 has generated strong interest for clinical use to treat HIV infection, especially in protocols targeting viral eradication or a functional cure. The use of IL-15 as an immune therapeutic agent against HIV infection is based on its effects as a growth factor and key regulator of cytotoxic responses mediated by both the innate (NK cells) and the adaptive (CTL) arms of the immune system. Using hetIL-15 treatment in the RM model for HIV infection, we have demonstrated that: (i) a regimen with increasing dosing (step-dose) of hetIL-15 is well tolerated by different routes of delivery and increases T lymphocytes (CD8, CD4 and gamma/delta) and NK cells with high granzyme content in peripheral blood, mucosal sites and LN. (ii) Importantly, hetIL-15 treatment promotes the entrance of cytotoxic (GrzB+) CD8+ T cells in the B cell follicles, areas within the LN where CTL are typically excluded and where SIV/HIV infected follicular helper CD4+ T cells reside. hetIL-15 treatment led to significant decrease in cell-associated viral RNA within the LN as well as in plasma viremia in SHIV infected macaques. (iii) We also showed that hetIL-15 can enhance ADCC in LN, which provides an additional mechanism of elimination of infected cells. We have also used optimized vectors to express IL-12 cytokine in animals. Efficient expression results in bioactive levels, which increase immune response after DNA vaccination, thus becoming important molecular adjuvant for our vaccines. We have also developed methods for large-scale isolation and purification of exosomes. We have shown that hetIL-15 is incorporated in exosomes and have produced sufficient quantities for animal experiments. We propose that the versatility of exosomes can be used for the delivery of immunotherapy exosomes to disease sites (tumor or lymphoid tissue). We developed methods for the efficient delivery of exosomes to tumor sites. Additional experiments in mouse tumor models have demonstrated the rapid interaction of lymphoid and myeloid cell networks resulting in changes in numbers and migration of different cell populations. Extensive transcriptomics and proteomics analysis has revealed additional pathways affected by hetIL-15 pharmacologically. Of note, we have studied the effects of hetIL-15 in the number and properties of Dendritic Cells (DC) in tumors. We have demonstrated that DC in tumors increase upon hetIL-15 treatment. DC participate in a network of cells that are induced during hetIL-15 treatment and in turn support more recruitment of effector cells in tumor sites. Experiments in mouse orthotopic models show that DC populations correlate with tumor regression and reveal additional beneficial effects of hetIL-15 in inducing or enhancing long term protective immune response against tumors. In experiments that show the importance of IL-15 on the development of immune response, we identified a systemic signature in blood of cytokines induced transiently after vaccination by the Pfizer mRNA vaccine. This signature includes increases in IL-15, IFN-gamma, and IP-10/CXCL10 after the 1st vaccination, which were enriched by tumor necrosis factor alpha (TNF-alpha) and IL-6 after the 2nd vaccination. In previously COVID-19-infected individuals, a single vaccination resulted in both strong cytokine induction and antibody titers similar to the ones observed upon booster vaccination in antigen-naive individuals, a result with potential implication for future public health recommendations. In an additional line of research, we have shown in collaborative work with colleagues in Oregon, Seattle and Uppsala that IL-15 trranscriptional signature predicts protection by another viral vaccine: The differential IL-15 gene set response to RhCMV/SIV vaccine strongly correlated with the pre-vaccination activity of this pathway, with reduced baseline expression of IL-15 response genes significantly correlating with higher vaccine-induced IL-15 signaling and subsequent vaccine protection, suggesting that a robust de novo vaccine-induced IL-15 signaling response is needed to program vaccine efficacy. The RhCMV/SIV vaccine imparts a coordinated and persistent induction of innate and adaptive immune pathways featuring IL-15, a known regulator of CD8+ T cell function, that support the ability of vaccine-elicited unconventionally restricted CD8+ T cells to mediate protection against SIV challenge.
Terms: <(TNF)-α><21+ years old><AIDS><AIDS Virus><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Acquired Immunologic Deficiency Syndrome><Adjuvant><Adoptive Cell Transfers><Adoptive Transfer><Adult><Adult Human><Affect><After Care><After-Treatment><Aftercare><Agonist><Animal Experiments><Animals><Antibody titer measurement><Antigens><Area><Autoregulation><B blood cells><B cell><B cell differentiation factor><B cell stimulating factor 2><B cells><B-Cell Differentiation Factor><B-Cell Differentiation Factor-2><B-Cell Stimulatory Factor-2><B-Cells><B-Lymphocytes><B-cell><BCDF><BSF-2><BSF2><Biology><Blast Transformation><Blastogenesis><Blood><Blood Plasma><Blood Reticuloendothelial System><Booster Immunization><CCR><CD4 Cells><CD4 Positive T Lymphocytes><CD4 T cells><CD4 helper T cell><CD4 lymphocyte><CD4+ T-Lymphocyte><CD4-Positive Lymphocytes><CD8><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><CD8B><CD8B1><CD8B1 gene><COVID-19><COVID19><CRG-2><CV-19><CV19><CXCL10><CXCL10 gene><Cachectin><Cancers><Cell Body><Cell Communication and Signaling><Cell Function><Cell Line><Cell Process><Cell Signaling><Cell physiology><Cell-Mediated Lympholytic Cells><CellLine><Cells><Cellular Expansion><Cellular Function><Cellular Growth><Cellular Physiology><Cellular Process><Clinical><Clinical Trials><Clone Cells><Collaborations><Complement><Complement Proteins><Cyclic GMP><Cytolytic T-Cell><Cytotoxic T Cell><Cytotoxic T-Lymphocytes><Cytotoxic agent><Cytotoxic cell><Cytotoxic drug><DNA><DNA Therapy><DNA Vaccines><DNA delivery><Dendritic Cells><Deoxyribonucleic Acid><Development><Disease><Disorder><Disseminated Malignant Neoplasm><Dose><Drug Kinetics><Edodekin Alfa><Effector Cell><Elements><Future><GMP lots><Gamma interferon><Gene Expression><Gene Transfer Clinical><Generalized Growth><Genes><Genetic Intervention><Goals><Granzyme><Growth><Growth Agents><Growth Factor><Growth Substances><Guanosine Cyclic Monophosphate><HIV><HIV Infections><HPGF><HTLV-III Infections><HTLV-III-LAV Infections><Hepatocyte-Stimulating Factor><Homeostasis><Human><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Hybridoma Growth Factor><IFI10><IFN-Gamma><IFN-beta 2><IFN-g><IFN-γ><IFNB2><IFNG><IFNγ><IL-12><IL-15><IL-15 Gene><IL-15 binding protein><IL-15 receptor><IL-15R><IL-6><IL12><IL15><IL15 Protein><IL15 gene><IL6 Protein><INP10><IP-10><Immune><Immune Interferon><Immune mediated therapy><Immune response><Immune system><Immunes><Immunological response><Immunologically Directed Therapy><Immunomodulation><Immunotherapeutic agent><Immunotherapy><Individual><Infiltration><Injections><Interferon Gamma><Interferon Type II><Interferon-gamma><Interleukin-12><Interleukin-15><Interleukin-15 Gene><Interleukin-15 Precursor><Interleukin-15 Precursor Gene><Interleukin-6><Intervention><Intervention Strategies><Intracellular Communication and Signaling><K lymphocyte><LAV-HTLV-III><LYT3><Light><Location><Lymph Node Reticuloendothelial System><Lymph node proper><Lymphadenopathy-Associated Virus><Lymphatic Tissue><Lymphatic cell><Lymphatic nodes><Lymphoblast Transformation><Lymphocyte><Lymphocyte Activation><Lymphocyte Function><Lymphocyte Stimulation><Lymphocyte Transformation><Lymphocytic><Lymphocytopenia><Lymphoid Cell><Lymphoid Tissue><Lymphopenia><MGC9721><MGC9721 Gene><MGI-2><MOB-1><Macaca><Macaque><Macrophage-Derived TNF><Malignant Neoplasms><Malignant Tumor><Mediating><Metastatic Cancer><Metastatic Malignant Neoplasm><Methods><Mice><Mice Mammals><Modeling><Modern Man><Molecular><Monocyte-Derived TNF><Murine><Mus><Myeloid Cells><Myeloid Differentiation-Inducing Protein><NK Cells><NKSF><Naked DNA Vaccines><Names><Natural Killer Cell Stimulatory Factor><Natural Killer Cells><Non-Polyadenylated RNA><Nuclear><Oregon><Pathway interactions><Patients><Pharmacokinetics><Pharmacology><Phase I Study><Photoradiation><Physiological Homeostasis><Plasma><Plasma Serum><Plasmacytoma Growth Factor><Population><Post-Transcriptional Control><Post-Transcriptional Regulation><Preparation><Process><Production><Proliferating><Property><Proteins Growth Factors><Proteomics><Protocol><Protocols documentation><Public Health><Publications><RNA><RNA Gene Products><RNA vaccine><RNA-based vaccine><Recombinant DNA Vaccines><Recombinants><Recommendation><Recovery><Regimen><Regulation><Regulatory T-Lymphocyte><Research><Reticuloendothelial System, Serum, Plasma><Ribonucleic Acid><Rodent><Rodentia><Rodents Mammals><Role><Route><SCYB10><SHIV><SIV><SIV Vaccines><Scientific Publication><Secondary Immunization><Signal Transduction><Signal Transduction Systems><Signaling><Simian Immunodeficiency Viruses><Site><Solid Neoplasm><Solid Tumor><Strains Cell Lines><Subcellular Process><T-Cells><T-Lymphocyte><T4 Cells><T4 Lymphocytes><T8 Cells><T8 Lymphocytes><TNF><TNF A><TNF Alpha><TNF gene><TNF-α><TNFA><TNFα><Technology><Testing><Therapeutic Agents><Tissue Growth><Treg><Tumor Necrosis Factor><Tumor Necrosis Factor-alpha><Tumor Tissue><Unresectable><Vaccination><Vaccine Adjuvant><Vaccines><Veiled Cells><Viral><Viral Vaccines><Viral reservoir><Viremia><Virus><Virus reservoir><Virus-HIV><Work><aPD-1><aPD1><adoptive cell therapy><adoptive cellular therapy><adulthood><allergic/immunologic body system><allergic/immunologic organ system><anti programmed cell death 1><anti-PD-1><anti-PD1><anti-cancer immunotherapy><anti-programmed cell death protein 1><antiPD-1><antiPD1><antibody titering><anticancer immunotherapy><arm><base><biological signal transduction><booster vaccination><cGMP><cancer immunotherapy><cell growth><clinical applicability><clinical application><clinical development><clinical material><corona virus disease 2019><coronavirus disease 2019><cultured cell line><cytokine><cytotoxic><deliver DNA><design><designing><developmental><exosome><experiment><experimental research><experimental study><expression vector><first in man><first-in-human><gIP-10><gene therapy><gene-based therapy><genetic therapy><genomic therapy><good manufacturing practice lot><host response><immune drugs><immune modulation><immune regulation><immune system response><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based cancer therapies><immune-based therapeutics><immune-based therapies><immune-based treatments><immuno therapy><immunogen><immunologic preparation><immunologic reactivity control><immunologic therapeutics><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><immunotherapeutics><immunotherapy agent><immunotherapy for cancer><immunotherapy of cancer><improved><inhibitor><inhibitor/antagonist><interest><interferon beta 2><interleukin-15 receptor><interventional strategy><killer T cell><lFN-Gamma><lymph cell><lymph gland><lymph nodes><lymphnodes><mRNA vaccine><mRNA-based vaccine><malignancy><migration><mouse model><mucosal site><murine model><neoplasm/cancer><novel><ontogeny><outcome following vaccination><outcome following vaccine><pathway><peripheral blood><phase 1 study><post treatment><post-transcriptional gene regulation><posttranscriptional control><posttranscriptional regulation><predictive signature><prevent><preventing><programs><recruit><regulatory T-cells><response><result following vaccination><result following vaccine><simian HIV><simian human immunodeficiency virus><simian immunodeficiency virus vaccines><social role><thymus derived lymphocyte><transcriptomics><tumor><vaccination outcome><vaccination result><vaccine efficacy><vaccine outcome><vaccine result><vector><viraemia><viral RNA><viral sepsis><virus RNA><virusemia><αPD-1><αPD1>